GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE315nnn/GSE315154/primary200OKOtherMus musculusOtherhttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315154GEOGSEfalseCRISPR/Cas9 Screen Reveals PRKCB-Mediated Phosphorylation of YBX1 Promotes Oxaliplatin Resistance in Colorectal CancerChemotherapy resistance remains a major obstacle in colorectal cancer (CRC) treatment. To systematically identify genes conferring resistance to oxaliplatin, a first-line chemotherapeutic agent, we performed a genome-wide CRISPR/Cas9 knockout screen in the murine CRC cell line CT26. We used a library targeting 1,412 drug-related genes with 11,396 unique sgRNAs. Cells were treated with either vehicle control or oxaliplatin for 7 days under selection pressure. Genomic DNA was then harvested and the abundance of each sgRNA was determined by deep sequencing. Comparison between treatment groups revealed significant depletion of sgRNAs targeting 67 genes in oxaliplatin-treated cells, indicating their potential role in promoting survival and resistance. The top-ranked candidate, PRKCB (Protein Kinase C Beta), was subsequently validated. This dataset provides a comprehensive resource of genetic determinants of oxaliplatin resistance in CRC.2026/07/01GSE315154GSM9422220GSM9422221GSM9422222GSM9422223GSM942222421273315154Mus musculus